Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-Fluoxetine SCHEMBL1200433 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8467346 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL570572 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL33947 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| R-Fluoxetine SCHEMBL3905325 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL7081402 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8911991 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL17436534 | 0.99 | SLC6A4 (0.97) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL3399076 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL7902048 | 0.99 | SLC6A4 (0.97) | SLC6A4MEN1KMT2ALMNASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 69043 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4746863-A1 | ENDOXIFEN COMPOSITIONS AND METHODS OF USE THEREOF AND SYNTHESIS THEREOF | Atossa Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026102563-A1 | DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2026-05-21 | — | — | WO | claimed |
| WO-2026102521-A1 | USE OF A PURINE COMPOUND FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MARVEL BIOTECHNOLOGY (CA) | 2026-05-21 | — | — | WO | claimed |
| CN-122036817-A | C-alkyl carbon glycoside and preparation method thereof | 江西师范大学 | 2026-05-15 | — | — | CN | claimed |
| CN-122035985-A | Magnetic eutectic solvent, preparation method and application thereof, pretreatment method of antidepressant-containing wastewater and quantitative detection method | 山西医科大学 | 2026-05-15 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739303-A2 | MDMA ENANTIOMER COMPOSITIONS AND METHODS FOR MODULATING AGGRESSION RESPONSE | EmpathBio, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| US-4626549-A | Treatment of obesity with aryloxyphenylpropylamines | ELI LILLY AND COMPANY (US) | 1986-12-02 | — | — | US | claimed |
| EP-0193355-A2 | Analgesic composition | ELI LILLY AND COMPANY (US) | 1986-09-03 | — | — | EP | claimed |
| EP-0193354-A2 | Analgesic composition | ELI LILLY AND COMPANY (US) | 1986-09-03 | — | — | EP | claimed |
| US-4594358-A | Administering (nor)floxetine before dextropropoxyphene | ELI LILLY AND COMPANY (US) | 1986-06-10 | — | — | US | claimed |
| US-4590213-A | Anti-anxiety method | ELI LILLY AND COMPANY (US) | 1986-05-20 | — | — | US | claimed |
| EP-0123469-A1 | Use of fluoxetine for the manufacture of an anti-anxiety agent | ELI LILLY AND COMPANY (US) | 1984-10-31 | — | — | EP | claimed |
| US-4444778-A | ANTISEROTONINE AGENTS | COUGHLIN SHAUN R | 1984-04-24 | — | — | US | claimed |
| US-4329356-A | Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane | ELI LILLY AND COMPANY (US) | 1982-05-11 | — | — | US | claimed |
| US-4083982-A | 3-(PARA-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3-PHENYL-PROPYLAMINE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1978-04-11 | — | — | US | claimed |
| US-4035511-A | 3-(P-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3-PHENYLPROPYLAMINE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1977-07-12 | — | — | US | claimed |